• Business & Finance

    Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update

    Bloomberg Six Reasons Asia’s Oil Refiners Aren’t Going Away Anytime Soon (Bloomberg) — Predictions of peak oil and the impending demise of fossil fuels will hit Asian oil refiners especially hard. The region is home to three of the top four oil-guzzling nations, and more than a third of global crude processing capacity. Yet, Asian refiners are expanding at a breakneck pace, even building massive new plants designed to run for at least half a century.What is going on?After a century of powering the world’s vehicles, oil refiners are having to plan for an oil-free future in mobility as cars  

    Comments Off on Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update
  • Business & Finance

    OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time

    Bloomberg There’s Plenty Worrying Investors as Europe’s Stocks Hit Records (Bloomberg) — European equities are at records, vaccination rates are picking up and central banks are funneling trillions of dollars into the economy. But there is still plenty that could go wrong, with a resurgent coronavirus outbreak, another missed summer holiday season and elections keeping investors up at night.While the pandemic turned 2020 into a stock market roller-coaster, 2021 has begun on a more optimistic note. The Stoxx Europe 600 Index has jumped 9.6{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6} this year and hit an all-time high in April, the VStoxx Index of euro-area volatility has  

    Comments Off on OpGen to Provide Business Update and Financial Results for the First Quarter 2021 on May 13th at 8:30 a.m. Eastern Time
  • Business & Finance

    Aspen Aerogels, Inc. Reports First Quarter 2021 Financial Results and Recent Business Developments

    NORTHBOROUGH, Mass., April 29, 2021 /PRNewswire/ — Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen“) today announced financial results for the first quarter of 2021, which ended March 31, 2021, and discussed recent business developments. Total revenue for the first quarter was $28.1 million compared to $28.4 million in the first quarter last year. First quarter net loss was $6.3 million compared to a net loss of $3.2 million in the first quarter of 2020. Net loss per share for the first quarter was $0.22 compared to $0.13 in the first quarter last year. Adjusted EBITDA for the  

    Comments Off on Aspen Aerogels, Inc. Reports First Quarter 2021 Financial Results and Recent Business Developments
  • Business & Finance

    KLDiscovery Inc. Announces Fourth Quarter 2020 Financial Results | Business & Finance

    MCLEAN, Va.–(BUSINESS WIRE)–Mar 17, 2021– KLDiscovery Inc. (“KLDiscovery” or the “Company”), a leading global provider of electronic discovery, information governance and data recovery services, announced today that revenue for the fourth quarter ended December 31, 2020 was $74.6 million versus $72.3 million in the third quarter of 2020, a 3{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6} increase quarter-over-quarter and a decrease of 7{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6} year-over-year compared to the fourth quarter 2019. Net loss for the fourth quarter of 2020 was $9.8 million compared to $12.7 million in the third quarter of 2020, an improvement of 23{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6} quarter-over-quarter and an improvement of 45{a25bda0f8ab6dac90e68079d6f038584ef6ac53f1f4621de3ad526e35cd6c0d6} compared to the fourth quarter  

    Comments Off on KLDiscovery Inc. Announces Fourth Quarter 2020 Financial Results | Business & Finance
  • Business & Finance

    Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights

    Cash position of €62 million at year-end provides runway until the end of H2 2022 Enrolment of SENS-401 Phase 2 SSNHL clinical study progressing Expanding internal gene therapy capabilities including AAV, analytical and process development Reported positive preliminary non-human primate data for the OTOF program In February 2021, extended Gene Therapy portfolio by adding a third program focused on the GJB2 mutations Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces today its full-year 2020 financial results  

    Comments Off on Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights